Table A1. Origins and molecular and phenotypic characteristics of Enterococcus faecalis isolates*.
| ID (other name) | Origin† | Setting | Sampling year | MLST† | PFGE‡ | Biofilm formation | Virulence-associated genes | PAI genes | Resistance profile |
|---|---|---|---|---|---|---|---|---|---|
| 31438-1 | IE patient | HA | 1997 | 97 | A | Weak | ebpA gelE hylA ef1896 ef2505 ace | cbh | None |
| 130529 | IE patient | HA | 2000 | 97 | A | Weak | ebpA gelE hylA ef1896 ef2505 ace | cbh | None |
| 67190 | IE patient | CA | 2002 | 97 | A | Weak | ebpA gelE hylA ef1896 ef2505 ace | cbh | None |
| 7330616-3 (D30) | Pig | NA | 2001 | 97 | A | Weak | ebpA gelE hylA ef1896 ef2505 ace | cbh | None |
| 28137 | IE patient | HA | 1996 | 72 | B | None | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 7684 | IE patient | HA | 1997 | 72 | B | Weak | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 33873 | IE patient | HA | 2002 | 72 | B | Medium | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 1293 | CD human | NA | 2003 | 72 | B | Medium | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 3527 | CD human | NA | 2006 | 72 | B | Medium | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 1745 | CD human | NA | 2004 | 72 | U1 | Weak | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | TET |
| 43674 | IE patient | CA | 1999 | 19 | C | Medium | ebpA gelE ef2505 hlyB ace | None | ERY TET |
| 2247 | CD human | NA | 2004 | 19 | C | Medium | ebpA gelE ef2505 hlyB ace | cbh esp | CIP ERY TET |
| 54869 | IE patient | HA | 1997 | 40 | D | Weak | ebpA gelE hylA ef2505 hlyB ace | cbh | KAN STR TET |
| 7330082-2 (D1) | Pig | NA | 2001 | 40 | D | Medium | ebpA gelE hylA ef2505 hlyB ace | cbh esp | None |
| 7330321-1 (D27) | Pig | NA | 2001 | 40 | D | Medium | ebpA gelE hylA ef2505 hlyB ace | cbh esp | CHL ERY KAN STR TET |
| 7331063-5 (D37) | Pig | NA | 2001 | 40 | D | None | ebpA gelE hylA ef2505 hlyB ace | cbh | STR |
| 7330887-1 (D32) | Pig | NA | 2001 | 40 | U2 | None | ebpA gelE hylA ef2505 hlyB ace | cbh | ERY STR |
| 26669 | IE patient | HA | 1998 | 21 | E | Weak | ebpA gelE hylA ef2505 hlyB ace | cbh | None |
| 3162 | CD human | NA | 2005 | 21 | E | Weak | ebpA gelE hylA ef2505 ace | cbh esp | TET |
| 105049 | IE patient | CA | 1997 | 306 | E | Medium | ebpA gelE hylA ef1896 ef2505 ace | cbh esp | None |
| 127801 | IE patient | CA | 1999 | 306 | F | Medium | ebpA gelE hylA ef1896 ef2505 ace | cbh esp | None |
| 2421 | CD human | NA | 2004 | 306 | F | Medium | ebpA gelE hylA ef1896 ef2505 ace | cbh esp | None |
| 57690 | IE patient | HA | 2000 | 22 | NA | Weak | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 20505-1 | IE patient | HA | 2000 | 30 | NA | Weak | ebpA gelE hylA ef1896 ef2505 ace | esp | TET |
| 100087 | IE patient | HA | 1999 | 41 | NA | Weak | ebpA gelE hylA ef1896 ef2505 ace | cbh esp | ERY KAN STR TET |
| 105158 | IE patient | HA | 1997 | 55 | NA | Medium | ebpA hylA ef1896 ef2505 hlyB ace | cbh esp | CHL ERY KAN STR TET |
| 134125 | IE patient | HA | 2000 | 55 | NA | Strong | ebpA hylA ef1896 ef2505 hlyB ace | cbh esp | CHL ERY KAN STR TET |
| 29783 | IE patient | HA | 1999 | 81 | NA | Medium | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh ef0571 | None |
| 120903 | IE patient | CA | 1999 | 192 | NA | Medium | ebpA gelE ef1824 hylA ef2505 hlyB ace | None | TET |
| 107137 | IE patient | HA | 2001 | 241 | NA | Weak | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh ef0571 | None |
| 83232 | IE patient | CA | 1997 | 326 | NA | Strong | ebpA gelE hylA ef1896 ef2505 ace | cbh esp | None |
| 1149 | CD human | NA | 2003 | 133 | NA | Strong | ebpA hylA ef1896 ef2505 ace | cbh | TET |
| 3392 | CD human | NA | 2005 | 133 | NA | Medium | ebpA hylA ef1896 ef2505 ace | cbh | None |
| 1732 | CD human | NA | 2003 | 141 | NA | None | ebpA gelE ef1824 hylA ef2505 hlyB ace | None | CIP |
| 1028 | CD human | NA | 2003 | 168 | NA | Strong | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 1309 | CD human | NA | 2003 | 168 | NA | Strong | ebpA gelE ef1824 hylA ef2505 hlyB ace | cbh | None |
| 1413 | CD human | NA | 2003 | 199 | NA | Medium | ebpA gelE ef1824 hylA ef2505 ace | cbh | None |
| 2174 | CD human | NA | 2004 | 206 | NA | Weak | ebpA hylA ef2505 ace | cbh | TET |
| 2041 | CD human | NA | 2004 | 327 | NA | Weak | ebpA hylA ef2505 ace | cbh | TET |
*MLST, multi-locus sequence typing; PFGE, pulsed-field gel electrophoresis; PAI, pathogenicity island; IE, infective endocarditis; CD, community-dwelling; HA, healthcare-associated infection; CA, community-acquired infection; NA, not applicable; CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin, KAN, kanamycin; STR, streptomycin; TET, tetracycline. †STs from 5 pig isolates (in italics) have been published previously (7); the remaining 14 pig isolates belonging to other STs (ST1, ST6, ST16, ST26, ST47, ST63, ST96, ST98, ST99, and ST100) were not included in further analysis. ‡Isolates with similar PFGE banding patterns (>82% relatedness) received the same letter designation (A–F) to reflect their genetic relatedness; highly divergent PFGE banding patterns were designated as unique (U) types (U1 and U2).